Associated Papers
Integrating evidence from protein domains to identify cancer driver mutations.
Ostroverkhova D et al.
Protein Science : a Publication of the Protein Society, 2026
41556616 (PubMed )
Supplement: PRO-35-e70422-s002.xlsx › Table_S1
Molecular landscape of ERBB2 alterations in 3000 advanced NSCLC patients.
Hong L et al.
Npj Precision Oncology, 2024
Similar genetic profile in early and late stage urothelial tract cancer.
Stormoen DR et al.
Journal of Cancer Research and Clinical Oncology, 2024
38976041 (PubMed )
Supplement: 432_2024_5850_MOESM2_ESM.xlsx › TCGA-cohort
ERBB2-Mutant Gastrointestinal Tumors Represent Heterogeneous Molecular Biology, Particularly in Microsatellite Instability, Tumor Mutation Burden, and Co-Mutated Genes: An In Silico Study.
Uchida S et al.
Current Issues in Molecular Biology, 2023
37754252 (PubMed )
Supplement: cimb-45-00468-s001.zip › Table_S1.xlsx › Sheet1
Plasma Genotyping at the Time of Diagnostic Tissue Biopsy Decreases Time-to-Treatment in Patients With Advanced NSCLC-Results From a Prospective Pilot Study.
Thompson JC et al.
Jto Clinical and Research Reports, 2022
35392653 (PubMed )
Supplement: mmc3.xlsx › All_data
Associations of HER2 Mutation With Immune-Related Features and Immunotherapy Outcomes in Solid Tumors.
Wang D et al.
Frontiers in Immunology, 2022
RNA-SSNV: A Reliable Somatic Single Nucleotide Variant Identification Framework for Bulk RNA-Seq Data.
Long Q et al.
Frontiers in Genetics, 2022
35846154 (PubMed )
Supplement: Table3.XLSX › BLCA_RNA_DNA_overlap
Targeting HER2 genomic alterations in non-small cell lung cancer.
Zeng J et al.
Journal of the National Cancer Center, 2021
Analysis of targeted somatic mutations in pleomorphic carcinoma of the lung using next-generation sequencing technique.
Manabe S et al.
Thoracic Cancer, 2020
32578376 (PubMed )
Supplement: TCA-11-2262-s003.xlsx › Sheet1
Mutational landscape and characteristics of ERBB2 in non-small cell lung cancer.
Wei XW et al.
Thoracic Cancer, 2020
The Immunogenic Potential of Recurrent Cancer Drug Resistance Mutations: An In Silico Study.
Punta M et al.
Frontiers in Immunology, 2020
33133066 (PubMed )
Supplement: Table_1.xlsx › Drivers-not-HR
Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity.
Robichaux JP et al.
Cancer Cell, 2019
High Frequency of Juxtamembrane Domain ERBB2 Mutation in Gastric Cancer.
Park S et al.
Cancer Genomics & Proteomics, 0
Select a paper to view details